头颈癌诊断前后肺炎球菌病、流感和COVID-19疫苗接种率的变化
该登记系统多中心研究纳入2018—2021年诊断的≥18岁丹麦头颈癌患者,计算诊断前后疫苗接种累积发病率及诊断后接种的发病密度。结果显示肺炎球菌疫苗和COVID-19疫苗累积发病率在诊断后升高,流感疫苗相近;诊断后第二个半年流感疫苗接种发病密度高于第一个半年。
要点
- 头颈癌诊断前后肺炎球菌疫苗累积发病率分别为8%和16%。
- 四价流感疫苗累积发病率分别为36%和38%,mRNA COVID-19疫苗为60%和89%。
- 诊断后第一个半年与第二个半年mRNA COVID-19疫苗发病密度分别为273和111每1000人月,IRR为0.38。
核心结论
- 研究显示头颈癌诊断后肺炎球菌疫苗和COVID-19疫苗累积接种率显著升高,但诊断前接种存在不足,提示需提高对疫苗接种选择和推荐的认知。
- 研究结果可作为未来推荐意见的参考。
研究设计与样本
- 基于登记系统的多中心研究,纳入2018—2021年诊断的≥18岁丹麦头颈癌患者。
- 通过计算累积发病率评估疫苗接种率,通过计算诊断后第一个半年和第二个半年疫苗接种发病密度探索接种时机。
主要发现
- 肺炎球菌疫苗累积发病率在头颈癌诊断前一年为8%,诊断后一年为16%。
- 四价流感疫苗累积发病率在诊断前一年为36%,诊断后一年为38%;mRNA COVID-19疫苗分别为60%和89%。
- 诊断后第一个半年与第二个半年mRNA COVID-19疫苗发病密度分别为273和111每1000人月随访(IRR 0.38,p < 0.001)。
- 诊断后第一个半年与第二个半年四价流感疫苗发病密度分别为28和51每1000人月随访(IRR 1.95,p < 0.001)。
- 诊断后第一个半年与第二个半年肺炎球菌疫苗发病密度分别为11和14每1000人月随访(IRR 1.28,p = 0.21)。
关键数值与推荐
- 原文未报告疫苗接种的具体推荐条款或阈值。
临床怎么用
- 原文未据此给出具体的临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumonia is one of the main contributors to non-cancer mortality among patients with head and neck cancer (HNC). This study aimed to determine the vaccine uptake for pneumococcal polysaccharide and conjugate vaccines, quadrivalent influenza vaccines, and mRNA COVID-19 vaccines before and after an HNC diagnosis. Furthermore, the study investigated the timing of vaccination after a cancer diagnosis. MATERIALS & METHODS: This register based multicentre study included Danish patients ≥ 18y diagnosed with HNC between 2018 and 2021. The vaccine uptake was assessed by calculating cumulative incidence (CI), while the timing of vaccination after an HNC diagnosis was explored by calculating incidence rates of vaccination the first and second half year after a cancer diagnosis. RESULTS: The cumulative incidence of vaccine uptake for pneumococcal vaccines was estimated to be 8 % and 16 % one year before and after an HNC diagnosis, respectively. The CIs were 36 % and 38 % for quadrivalent influenza vaccines, respectively, whereas the CIs of vaccine uptake for mRNA COVID-19 vaccines were 60 % and 89 %. The IR of mRNA COVID-19 vaccinations the first half year after HNC diagnosis were 273 per 1000 person-months of follow-up (PMFU) and 111 per 1000 PMFU the second half year, respectively (IRR: 0.38, p < 0.001). Comparing the same periods, the IR of quadrivalent influenza vaccination was 28 per 1000 PMFU and 51 per 1000 PMFU (IRR: 1.95, 0 < 0.001). The IRs of pneumococcal vaccinations were 11 per 1000 PMFU and 14 per 1000 PMFU (IRR 1.28, p = 0.21). CONCLUSIONS: Although our study shows a significant increase in pneumococcal and COVID-19 vaccine uptake after HNC diagnosis, a gap remains in vaccine uptake before diagnosis, underscoring the need for increased awareness of vaccination options and recommendations. Our findings could serve as a reference for future recommendations.
引用
- Eiberg MF, Rezahosseini O, Bukan KB, et al. Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis. Vaccine. 2024. PMID: 38789370. doi:10.1016/j.vaccine.2024.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。